- Home
- XIFR vs COLL Comparison
XIFR vs COLL Comparison
Compare XIFR & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XIFR
- COLL
- Stock Information
- Founded
- XIFR 2014
- COLL 2002
- Country
- XIFR United States
- COLL United States
- Employees
- XIFR N/A
- COLL N/A
- Industry
- XIFR
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- XIFR
- COLL Health Care
- Exchange
- XIFR NYSE
- COLL Nasdaq
- Market Cap
- XIFR 874.5M
- COLL 910.2M
- IPO Year
- XIFR N/A
- COLL 2015
- Fundamental
- Price
- XIFR $9.51
- COLL $29.85
- Analyst Decision
- XIFR
- COLL Strong Buy
- Analyst Count
- XIFR 0
- COLL 5
- Target Price
- XIFR N/A
- COLL $43.60
- AVG Volume (30 Days)
- XIFR 2.0M
- COLL 456.4K
- Earning Date
- XIFR 04-22-2025
- COLL 05-08-2025
- Dividend Yield
- XIFR 28.48%
- COLL N/A
- EPS Growth
- XIFR N/A
- COLL 43.56
- EPS
- XIFR N/A
- COLL 1.86
- Revenue
- XIFR $1,230,000,000.00
- COLL $631,449,000.00
- Revenue This Year
- XIFR N/A
- COLL $20.00
- Revenue Next Year
- XIFR N/A
- COLL $3.93
- P/E Ratio
- XIFR N/A
- COLL $16.00
- Revenue Growth
- XIFR 14.10
- COLL 11.41
- 52 Week Low
- XIFR $7.97
- COLL $27.28
- 52 Week High
- XIFR $35.15
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- XIFR N/A
- COLL 50.32
- Support Level
- XIFR N/A
- COLL $29.33
- Resistance Level
- XIFR N/A
- COLL $30.84
- Average True Range (ATR)
- XIFR 0.00
- COLL 0.84
- MACD
- XIFR 0.00
- COLL 0.07
- Stochastic Oscillator
- XIFR 0.00
- COLL 56.29
About XIFR XPLR INFRASTRUCTURE LP
NextEra Energy Partners LP is formed to acquire, manage, and own contracted clean energy projects. It owns interests in wind and solar projects in North America, as well as natural gas infrastructure assets in Texas. Renewable energy assets consist of wind, solar, and solar-plus-storage projects and a stand-alone battery storage project, as well as contracted natural gas pipeline assets. Renewable energy sales generate maximum revenue for the company.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.